- Home
- WAI vs CANF Comparison
WAI vs CANF Comparison
Compare WAI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAI
- CANF
- Stock Information
- Founded
- WAI 2018
- CANF 1994
- Country
- WAI China
- CANF Israel
- Employees
- WAI N/A
- CANF N/A
- Industry
- WAI
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- WAI
- CANF Health Care
- Exchange
- WAI NYSE
- CANF Nasdaq
- Market Cap
- WAI 14.8M
- CANF 14.8M
- IPO Year
- WAI 2023
- CANF N/A
- Fundamental
- Price
- WAI $3.44
- CANF $1.03
- Analyst Decision
- WAI
- CANF Strong Buy
- Analyst Count
- WAI 0
- CANF 2
- Target Price
- WAI N/A
- CANF $14.00
- AVG Volume (30 Days)
- WAI 673.2K
- CANF 129.3K
- Earning Date
- WAI 08-24-2025
- CANF 04-14-2025
- Dividend Yield
- WAI N/A
- CANF N/A
- EPS Growth
- WAI N/A
- CANF N/A
- EPS
- WAI N/A
- CANF N/A
- Revenue
- WAI $3,750,352.00
- CANF $674,000.00
- Revenue This Year
- WAI N/A
- CANF $461.72
- Revenue Next Year
- WAI N/A
- CANF N/A
- P/E Ratio
- WAI N/A
- CANF N/A
- Revenue Growth
- WAI N/A
- CANF N/A
- 52 Week Low
- WAI $1.38
- CANF $0.98
- 52 Week High
- WAI $20.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- WAI N/A
- CANF 39.89
- Support Level
- WAI N/A
- CANF $1.02
- Resistance Level
- WAI N/A
- CANF $1.09
- Average True Range (ATR)
- WAI 0.00
- CANF 0.04
- MACD
- WAI 0.00
- CANF -0.00
- Stochastic Oscillator
- WAI 0.00
- CANF 6.67
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides some essential business services in China to young and emerging companies, including corporate business training services, which mainly focus on knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising; and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).